1.Interphase FISH of amniocytes in the third trimester
Zeshan YOU ; Jia HUANG ; Jiansheng CHEN
Chinese Journal of Perinatal Medicine 1998;0(01):-
Objective To study the interphase FISH of cells from aminotic fluid in the third trimester prospectively. Methods Amniotic fluid (5ml) was obtained in 32 pregnant women in the third trimester who underwent cordocentesis for karyotyping. FISH was performed on uncultured am niocytes and the results were compared with karyotypes. Results Abnormal aneuploid were identified in 6 cases among the 32 women. The FISH results were consistent with the karyotypes. Conclusions Interphase FISH in third-trimester amniocentesis can provide an accurate clinical diagnosis on common aneupoidies.
2.Selective pregnancy reduction in second trimester
Zeshan YOU ; Qun FANG ; Jiansheng CHEN
Chinese Journal of Perinatal Medicine 1998;0(02):-
Objective To investigate selective pregnancy reduction in second-trimester and its notices. Methods Selective pregnancy reduction in 19 cases of multiple pregnancy during 12~25 gestational age was performed,including 6 cases of twins,1 cases of triplets,1 case of quadruplet and 1 case of sextuplet. Ultrasonographically guided transabdominal intracardiac injection of high concentrate potassium chloride (KCl) solution was used. Results Performances of selective feticide in all twins were successful,except one monochorionic twins. In 11 cases of triplets,one case was aborted,one case was monozygotic triplet. Selective feticide was performed successfully in 7 of the rest 9 cases and the quadruplet Two cases were aborted after the procedure. The sextuplet was aborted after feticide. Conclusion Multifetal pregnancy reduction can be successfully performed in the second trimester without severe maternal complications. But abortion might occur afterwards. It is possible to reduce the abortion rate if monozygotic twin or triplet can be excluded before feticide,choosing the gestational sac which near the fundus,reducing the amniotic fluid volume of the target fetus or postponing feticide.
3.Thyroid Function Change in Pregnant Women with Different Types of Gestational Diabetes Mellitus
Aiyue CHEN ; Jie LI ; Zhuyu LI ; Qin ZHANG ; Li LI ; Shanyang HE ; Zeshan YOU ; Liqun LIU
Journal of Sun Yat-sen University(Medical Sciences) 2017;38(3):443-447
[Objective] To investigate the relationship of different types of gestational diabetes mellitus (GDM) and thyroid function.[Methods] A Total of 3846 cases,which received prenatal examination,delivered in the Eastern Hospital of the First Affiliated Hospital,Sun Yat-sen University and performed a 75 g oral glucose tolerance test (75 g 0GTT) at 24-28 gestational weeks,from Jan 1st,2014 to Dec 31st,2015,were divided into 2 groups.Normal blood glucose group:the result of OGTT (fasting plasma glucose,1 hour glucose and 2 hour glucose) was normal;Gestational diabetes mellitus group (GDM group):the result of 0GTT was abnormal.GDM group were divided into Ⅰ,Ⅱ,and lⅢ.GDM Ⅰ defined as one abnormal blood glucose of result.GDM Ⅱ:two abnormal blood glucose.GDM Ⅲ:three abnormal blood glucose.1868 cases of healthy pregnant women were reselected as the control group.TSH,FT4 and TPO Ab were detected in two groups.Analysis of Variance,Mann-Whitney U test,Kruskal Wallis rank test or Fisher's test was used for statistical analysis.[Result] There were statistically significant difference in TSH,FT4 between GDM subgroup and control group (P =0.012,P =0.002).TSH median trend to increase in GDM Ⅱ,and FT4 median trend to decrease in GDM Ⅱ.The Prevalence of hypothyroidism in GDM Ⅱ and GDM Ⅲ were higher than those in control group.[Conclusion] The GDM group with two or three abnormal blood glucose had a higher incidence thyroid gland dysfunction,especial with subclinical hypothyroidism.We should fully test the thyroid function,treat diabetes as early as possible and improve the pregnancy outcome as we could.
4.Decreased Expression of Long Non-Coding RNA GAS5 in Ovarian Cancer Patients and Its Clinical Significance
Jie LI ; Yinguang LI ; Aiyue CHEN ; Zhuyu LI ; Wenhui HOU ; Zeshan YOU
Journal of Sun Yat-sen University(Medical Sciences) 2017;38(5):746-751
[Objective]Dysregulated long noncoding RNAs(lncRNAs)have been found involved in human diseases,including cancers. Long non-coding RNA growth arrest-specific 5(GAS5)was reported to be dysregulated in different types of cancers. Howev-er,the role of GAS5 in ovarian cancer remains elusive.[Methods]In the present study,the expression of GAS5 was detected in 108 ovarian cancer tissues and compared adjacent normal tissues by quantitative real-time PCR(qRT-PCR).[Results]The results showed that the expression levels of lncRNA GAS5 were significantly decreased in cancer tissues(P=0.0004),and it was negatively correlated with tumor size(<5 cm vs.>5 cm,P<0.0001),invasion depth(T1-T2 vs. T3-T4,P=0.0021),and tumor grade(Ⅰ~Ⅱgrades vsⅢ~Ⅳgrades,P=0.0086)in ovarian cancer patients. Kaplan-Meier analysis demonstrated that decreased lncRNA GAS5 expression contributed to poor disease-free survival and overall survival.[Conclusion]In conclusion ,our study suggested that decreased lncRNA GAS5 expression may beidentified as a potential poor prognostic biomarker in ovarian cancer.
5.Effect of Chinese Medicine on Signaling Pathways Related to Hepatocellular Carcinoma and Its Potential Mechanism: A Review
Peirong QIU ; Zeshan CHEN ; Wenlin ZHU ; Peichun PENG ; Jitian WU ; Yulian LI ; Xin DENG
Chinese Journal of Experimental Traditional Medical Formulae 2022;28(23):264-272
Hepatocellular carcinoma (HCC), an insidious malignant tumor with high incidence and lethality, poses a major threat to physical and mental health of human beings. The pathological mechanism needs to be further studied. Surgery, radiotherapy, chemotherapy, and targeted drugs are effective but induce many adverse reactions. Traditional Chinese medicine (TCM) has unique advantages and abundant clinical experience in the treatment of HCC. There has been an explosion of research on the pathways, targets, and mechanism of TCM against HCC from the perspective of molecular biology. According to previous research, Chinese medicinals or compound Chinese medicine prescriptions, directly or indirectly prevent the occurrence and progression of HCC through multiple pathways and targets, which is closely related to the pathophysiological processes such as cell proliferation, metastasis, apoptosis, autophagy, inflammatory response, and immune response. This paper summarizes and analyzes research on the action pathways and mechanisms of Chinese medicine against HCC. Specifically, isoliquiritigenin, dendrobium candidum and Yexiazhu compound Ⅱ regulate phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway to inhibit the growth, proliferation and metastasis of tumor cells. Toad venom and dioscorea zingiberensis induce and enhance HCC autophagy by modulating mammalian target of rapamycin (mTOR) signaling pathway. Myricetin, asparagus, and Biejiajian Wan regulate mitogen-activated protein kinase (MAPK) signaling pathway to promote HCC cell cycle arrest, inhibit angiogenesis, and induce apoptosis. Polygonum odoratum, tetragonum, and plantainoside modulate nuclear factor-kappa B (NF-κB) to inhibit inflammatory response and HCC metastasis and reduce drug resistance. Quercetin and erigeron breviscapus control the Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway to suppress epithelial-mesenchymal transition (EMT) and remodel cytoskeleton. This paper is expected to lay a theoretical basis for the in-depth research on and clinical application of Chinese medicine in the treatment of HCC.
6.Research advances in nano-drug delivery system in liver cancer treatment
Miaodong WANG ; Zeshan CHEN ; Peichun PENG ; Xin DENG
Journal of Clinical Hepatology 2022;38(8):1906-1912
Traditional surgical resection, radiotherapy, and chemotherapy still play a dominant role in the treatment of liver cancer; however, their application in liver cancer patients is often limited by the toxic and side effects, unstable efficacy, and unclear targets of chemotherapeutic drugs. Therefore, in order to improve the efficacy of drugs in the treatment of liver cancer, nanomedicine, which has been developed in the biomedical field in recent years, has attracted more and more attention. Nano-drug delivery system has been gradually applied in clinical research for its advantages of low toxicity, wide bioavailability, controllable drug release, and good stability. This article focuses on the latest research advances in nano-drug delivery system in the treatment of liver cancer.